Reporter brief
Fish oil with metformin did not yet reduce atherosclerosis markers in women with PMOS: RCT protocol.
What happened
This is a protocol paper describing a planned RCT, not results from a completed trial. The study will randomize 146 overweight or obese women aged 25-45 with PMOS and elevated triglycerides or apoB to receive either fish oil (5.96 g/day) or placebo for 12 months alongside standard metformin therapy. Primary outcomes are carotid intimal-medial thickness, carotid plaque height, and left ventricular strain; secondary outcomes include blood lipids and glucose-insulin measures.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Women aged 25-45 years with polyendocrine metabolic ovarian syndrome (PMOS), overweight or obesity (BMI >25 kg/m²), and elevated fasting plasma triglyceride or apoB levels
- Design
- Rct
- Sample
- 146
- Journal
- BMJ Open
- Published
- Sep 18, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Omega-3 fatty acids timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.